REG - ValiRx PLC - Collaborative Services Agreement

ValiRxAnnouncement

14/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230814:nRSN1439Ja&default-theme=true

RNS Number : 1439J  ValiRx PLC  14 August 2023

ValiRx PLC

("ValiRx" or the "Company")

Collaborative Services Agreement

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health, announces that the
CompanyÕs wholly owned subsidiary, Inaphaea BioLabs Limited ("Inaphaea"), has
entered into a collaborative services agreement with Agility Life Sciences
Limited ("Agility") ("Collaborative Services Agreement").

The Collaborative Services Agreement recognises the synergy between Inaphaea's
growing capabilities as a translational contract research organisation
(tCRO®) and Agility's capabilities for formulation development and
optimisation, pre-formulation studies and analysis.

Under the agreement, service users of Inaphaea will be able to benefit from
Agility's capabilities in a single service contract with Inaphaea and
similarly, service users of Agility will be able to access Inaphaea's
capabilities through their service contract with Agility.  This will enable a
coherent, single point of contact for service users to formulate and test
their drug candidates.

Dr Suzy Dilly, CEO at ValiRx explains "We have appreciated the skills and
creativity displayed by Agility during the two projects we have run with them,
so we're delighted to be able to offer these capabilities to our service
users, as well as to continue using these capabilities for our in-house
programmes.

"In a comparative manner to our collaborative services agreement with
Physiomics announced in April 2023, this new arrangement with Agility further
expands the Inaphaea service capability.  This agreement is very much
reciprocal, and we expect to be able to offer our services to Agility
customers just as much as offering their services to ours."

Professor Claire Thompson, CEO at Agility commented "We are really excited
about entering into this Collaborative Service Agreement with Inaphaea. This
will enable our clients to take the next steps in their development programmes
by testing their prototype formulations in the Inaphaea cell based studies.
 We believe this will be beneficial to both companies as well as to our
clients, creating a more comprehensive scientific environment, and
accelerating development timelines."

The Directors of the Company take responsibility for this announcement.

For more information, please contact:

 

 ValiRx plc                                                     Tel: +44 (0) 2476 796496

                                                                www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                                          Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 Inaphaea BioLabs Limited                                       www.inaphaea.com (http://www.inaphaea.com/)

 Dr Andrew Carnegie, Head of Strategic Commercial Development   Andrew.Carnegie@inaphaea.com (mailto:Andrew.Carnegie@inaphaea.com)

 V Formation (Public Relations)                                 +44 (0) 115 787 0206

                                                                www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton Ð Senior PR Executive

 Sue Carr - Director                                            lucy@vformation.biz

                                                                sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)               Tel: +44 (0) 20 7213 0880

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Cenkos Securities plc (Joint Broker)                           Tel: +44 (0) 20 7397 8900

 Dale Bellis/Michael Johnson (Sales)

 Callum Davidson/Giles Balleny (Corporate Finance)
 Turner Pope Investments (Joint Broker)                         Tel: +44 (0) 20 3657 0050

 James Pope / Andy Thacker

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and womenÕs health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRxÕs portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

About Agility Life Sciences

Agility Life Sciences is an award-winning CDMO, accelerating your milestones
and futureproofing your products.  Agility turns badly behaved molecules into
smart formulations which give them the best chance of success in preclinical
studies, and enable them to be accelerated to clinic.

Their core expertise is in developing formulations for small molecules and
peptides for various routes of administration including oral, ocular, IV,
intranasal and topical.

The ÒFast Futureproof FormulationsÓ approach always starts with an end in
mind, developing products which enable molecules to be accelerated from
discovery to clinic. Developing and manufacturing formulations to meet the
needs of their clients includes:

 

¥ Overcoming solubility and permeability issues.

¥ Immediate, controlled and sustained release.

¥ Formulations and analytical methods suitable for preclinical safety and
efficacy studies, including GLP tox studies.

¥ Clinical and commercial prototypes.

¥ Reverse engineering of existing products.

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRNKNBPPBKDOFD